Identification of biomarkers of shrinkage modes after neoadjuvant therapy in HER-2 positive breast cancer
The nomogram could accurately predict shrinkage modes after NAT, and may help guide the individualized selection of breast conserving surgery candidates after NAT. RUVBL1-AS1 might be a promising therapeutic target of paclitaxel-based chemotherapy inHER2+ breast cancer.
Authors
- Zhao Bi (ORCID: https://orcid.org/0000-0001-9546-1704)
- Wenhao Zheng (ORCID: https://orcid.org/0000-0002-9618-2456)
- Pengfei Qiu (ORCID: https://orcid.org/0000-0001-8644-1445)
- Xianrang Song
- Yiyu Lu (ORCID: https://orcid.org/0000-0001-9325-1658)
- Yue Zhang (ORCID: https://orcid.org/0009-0000-5690-6117)
- Yongsheng Wang (ORCID: https://orcid.org/0000-0001-6252-684X)
- Peng Chen (ORCID: https://orcid.org/0000-0002-5318-6668)
- Yanbing Liu (ORCID: https://orcid.org/0000-0001-9849-7948)
- Xingguo Song
Institutions
- People’s Hospital of Rizhao (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1097/js9.0000000000002349
- Citations
- 5
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.68